Table 2:
Description of study cohort
| Variable | NAC treated Cohort N (%) |
Observation arm n (%) |
p-value |
|---|---|---|---|
| Total | 24 (100) | 28 (100) | |
| Age at first Cisplatin dose, years | |||
| 0-5 | 9 (38) | 12 (43) | 0.485 |
| 6-10 | 7 (29) | 4 (14) | |
| ≥11 | 8 (33) | 12 (43) | |
| Sex | |||
| Male | 14 (58) | 19 (68) | 0.568 |
| Female | 10 (42) | 9 (32) | |
| Race | |||
| White | 20 (83) | 16 (57) | 0.087 |
| Black or African American | 1 (4) | 2 (7) | |
| Asian & Pacific Islander | 2 (8) | 2 (7) | |
| Other/Not Reported | 1 (4) | 8 (29) | |
| Ethnicity | |||
| Hispanic/Latinx | 13 (54) | 18 (64) | 0.573 |
| Not Hispanic/Latinx | 11 (46) | 10 (36) | |
| Tumor type | |||
| Hepatic tumor | 5 (21) | 4 (14) | 0.008 |
| CNS tumor | 9 (38) | 10 (36) | |
| Osteosarcoma | 10 (42) | 5 (18) | |
| Other | 0 (0) | 9* (32) | |
| Disseminated disease at diagnosis | |||
| No | 24 (100) | 6 (21) | < 0.001 |
| Yes | 0** (0) | 22 (79) | |
| Starting cisplatin dose/day, mg/m2 | |||
| Median (range) | 104.35 (75.2, 142.0) | 104.00 (68.5, 254.4) | 0.920 |
| Cumulative Cisplatin dose, mg/m2 | |||
| Median (range) | 460.85 (202.2, 952.8) | 399.25 (74.1, 603.2) | 0.069 |
| Reduction in cisplatin dose | |||
| No | 19 (79) | 22 (79) | 1.000 |
| Yes | 5 (21) | 6 (21) | |
| Pretreatment Cranial radiation | |||
| No | 19 (79) | 24 (86) | 0.716 |
| Yes | 5 (21) | 4 (14) | |
| Autologous stem cell transplant | |||
| No | 22 | 24 | 0.674 |
| Yes | 2 | 4† | |
| VPS prior to cisplatin | |||
| No | 18 (75) | 22 (79) | 1.000 |
| Yes | 6 (25) | 6 (21) |
*
Other diagnosis (n = 9): Germ cell tumor (5), Neuroblastoma (3), and NUT midline carcinoma (1); VPS = ventriculoperitoneal shunt;
**
Disseminated tumors were ineligible for NAC treatment.
†
2 did not receive hearing evaluations post-transplant.